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Original Article
Abstract
Purpose: Lymphoceles form part of target volume during adjuvant radiation for cervical cancer. The impact of lymphocele on
doses to adjacent organs at risk (OAR) has not been studied. The present study was designed to investigate the same. Methods:
From January 2011- December 2013 all patients were evaluated for presence of postoperative lymphocele. Planned target vol-
ume (PTV) was generated with and without lymphocele volume. Intensity modulated radiation therapy (IMRT) plans were
generated and dose to OARs was determined. The impact of lymphocele volume on OAR dose was determined by Spearman
rank test and Wilcoxon sign rank sum test was performed to determine the impact of lymphocele on OAR dose. Results: A total
of 11/93 patients had postoperative lymphoceles. Of these 63% were located in internal iliac region. The median lymphocele
volume at simulation was 42.8 cc (range 6.4-105cc) and remained almost stable at 44 cc (range 3-100 cc) at fifth week of radia-
tion. Negative correlation was observed between mean lymphocele volume and dose to bladder, rectum and bowel bag. Pres-
ence of lymphocele led to reduction in V30 and V40 of bladder (84 cc vs 77 cc, p = 0.004; 68 cc vs 63 cc; p = 0.01) and rectum
(87 cc vs 80 cc, p = 0.0001; 73.5 cc vs 65 cc, p = 0.01) and V15 of bowel bag (843 cc vs 804 cc; p = 0.01). Conclusion: Presence of
lymphoceles displaced OARs leading to reduction in high dose volumes of rectum and bladder.
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Introduction
Lymphocele is defined as an extra-peritoneal space which
lacks epithelial lining and is filled with lymph. It is a com-
mon complication after gynecological oncological surgeries
where pelvic lymphadenectomy plays an important role, for
staging as well as therapeutic purpose.1 The incidence of
lymphoceles has been reported to range from 16. 4% to as
high as 49% in various earlier series. However, with the im-
provement in surgical expertise, it has reduced to less than
6%.2, 3 Other common surgeries related with higher inci-
dence of lymphoceles include urological surgeries and renal
transplantation. Lymphoceles usually appear between 2-8
weeks after surgery and majority of them resolve spontane-
ously, usually within 6 months after surgery.4 The volume of
lymphocele is dependent on type of surgery, extent of lymph
node dissection, surgeons’ skills, etc.5 Lymphoceles, if small,
are usually asymptomatic and are managed conservatively.
The indications for active management include large lym-
phoceles causing pressure effects, infection or deep vein
thrombosis.
Lymphoceles are included in target volume for patients re-
ceiving post-operative radiotherapy for cervical carcinoma as
recommended by standard RTOG guidelines.6 Although,
small volume lymphoceles may not change the target vol-
ume, larger volume of lymphoceles may require substantial
modification of standard contours and may lead to an in-
crease in dose to normal pelvic organs like bladder, rectum,
small bowel and sigmoid. However there is no literature to
support or reject this hypothesis. The present study was un-
dertaken to evaluate the impact of post-operative lympho-
celes on planning target volume (PTV) and adjacent organs
at risk (OAR) in cohort of women undergoing adjuvant pel-
vic radiation.
Methods and Materials
Radiation planning computerized tomography scans of all
patients scheduled to undergo adjuvant chemoradiation from
January 2011- December 2013 within the context of on on-
going phase III randomized trial of adjuvant radiation were
reviewed to evaluate presence of post-operative lymphocele.7
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Detailed characteristics related to lymphocele like its loca-
tion, volume and laterality was recorded. Planning target
volume (PTV) was delineated according to the standard
guidelines for post-operative radiotherapy.6 In addition,
lymphocele was delineated as clinical target volume (CTV)
lymphocele and a margin of 0.5 cm was generated to obtain
PTV lymphocele. Two PTV volumes i.e. with and without
including PTV lymphoceles were generated and intensity
modulated radiation therapy (IMRT) plans were generated
using Helical Tomotherapy. OARs included bladder, rectum,
sigmoid, small and large bowel loops. Highest priority was
given for PTV coverage. Amongst OARs, highest priority
was given to small bowel sparing. To evaluate impact of
presence of lymphocele doses to OARs with and without
lymphocele were compared using Wilcoxon sign rank sum
test and correlation between lymphocele volume and doses
to OARs was studied by Spearman’s rank test.
All patients underwent adjuvant chemoradiation and vaginal
brachytherapy. Adjuvant radiation included 50 Gy/ 25 frac-
tions/ 5 weeks with concurrent weekly cisplatin (40 mg/m2 )
followed by 2 sessions of high dose rate vaginal brachy-
therapy (6 Gy each delivered a week apart). As we had access
to daily images for patients randomized to Tomotherapy
arm, the temporal changes in lymphocele volume was rec-
orded on weekly basis. Images were also assessed for any
clinically significant reduction or increase in volume that
may necessitate adaptive re-planning. For those randomized
to conventional arm Computerized Tomography (CT) images
obtained at the time of intravaginal brachytherapy were
assessed to record pre and post RT changes in lymphocele
volume. Follow up CT images were also reviewed for all
patients to evaluate temporal changes after completion of
chemo-radiation.
TABLE 1: Table depicting indications of treatment, delivered treatment and acute toxicity during treatment.
Patient Age(yrs) Indications of Adjuvant RT Planned Treatment Acute Toxicity
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TABLE 2: Characteristics of target volumes and organs at risk.







































































Overall 11/93 (11.8%) patients had pelvic lymphoceles at the
time of referral for adjuvant radiation. The median time from
surgery in this cohort was 2 months (range 2-4 months). The
baseline reasons for indications of adjuvant radiation, treat-
ment received and acute toxicities on treatment are listed in
Table 1. The presence of lymphocele did not lead to any
symptoms. One patient had large volume of pelvic lympho-
cele (patient 5) at presentation, however as it was not symp-
tomatic, hence no intervention was offered. The most com-
mon location of lymphocele was near the internal iliac ves-
sels and was observed in 63% patients. The location, volume
and laterality of lymphoceles and PTV volumes with and
without lymphoceles is depicted in Table 2. The temporal
changes in lymphocele volumes was available in 9/11 pa-
tients. While weekly volumes were available for patients
treated with Tomotherapy, week 1 and week 5 volumes were
available in 6 patients those treated with conventional radia-
tion. The median lymphocele volume at the time of radiation
planning was 42.8 cc (range 6.4-105cc) and remained almost
stable at 44 cc (range 3-100 cc) in the fifth week of radiation.
Only one patient had significant increase in the volume of
lymphocele from 90 cc at the time of planning to 105 cc at
first week MVCT scan, which required adaptive replanning
(Table 3). However over the course of treatment the lym-
phocele volume remained stable and was 90 cc in the last
week of radiation.
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1 Presacral Midline 103.30 91.00 87.00 80.00 70.70 67.00
2 External
Iliac
Unilateral 07.60 N/A* N/A* N/A* N/A* 07.50
3 Internal
Iliac
Unilateral 03.43 06.40 03.88 03.61 03.44 03.00
4 Internal
Iliac
Bilateral 107.17 N/A* N/A* N/A* N/A* 100
5 Internal
Iliac
Bilateral 90.33 105.00 N/A* N/A* N/A* 90
6 Presacral Midline 77.22 N/A* N/A* N/A* N/A* 89.00
7 Internal
Iliac
Unilateral 05.96 24.00 23.80 N/A* 20.70 17.67
8 External
Iliac
Bilateral 14.66 N/A* N/A* N/A* N/A* N/A*
9 Internal
Iliac
Unilateral 29.08 N/A* N/A* N/A* N/A* N/A*
10 Internal
Iliac
Unilateral 11.24 N/A* N/A* N/A* N/A* 09.50
11 Internal
Illiac
Bilateral 21.63 27.00 24.80 22.00 19.10 19.10
* Not available: Lymphocele volumes were not available for patients treated with conventional techniques and 2 patients treated with
Tomotherapy.
FIG. 1: Figure depicting dose distribution dose volume histogram with and without lymphocele. Figure 1A-C demonstrate dose wash and DVH
for planned target volume without lymphocele (lymphocele delineated in light blue). Figure 1D-F demonstrate dose wash and DVH for planned
target volume modified to include lymphocele. While most of the OAR’s were not impacted in this particular case including lymphocele in-
creased the sigmoid doses
The PTV and OAR doses with and without lymphocele
volume is depicted in Table 4 While small volume lympho-
celes did not lead to a statistically significant increase in
OAR dose, The presence of large lymphoceles reduced the
OAR doses by pushing OARs like bladder and bowel outside
the true pelvis. Specifically we observed a reduction in vol-
ume of bladder and rectum receiving 30 and 40 Gy. While
no reduction was observed in small bowel doses we observed
reduction in V15 Gy for large bowel and bowel bag. As most
of the patients had lymphoceles corresponding to internal
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iliac lymph node region we could not specifically evaluate
the impact of location of lymphocele on OAR dose. On cor-
relation between lymphocele volumes with doses to OARs,
there was negative correlation between mean lymphocele
volume and dose to bladder, rectum and bowel bag, which
was not seen for sigmoid colon, small and large bowel when
analyzed separately (Table 5). A sample isodose wash and
dose volume histogram with and without lymphocele is de-
picted in Figure 1.
TABLE 4: Impact of Lymphocele Inclusion in PTV on dose received by OARs.
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On follow up imaging, all but one patient had resolution of
lymphocele, with a median time to resolution being 6.5
months (range 4-11). In a patient with persistent lymphocele
at 12 months post-surgery, lower limb oedema and pain was
observed due to pressure effect and pigtail drainage had to be
performed for symptomatic relief. Cytological there was no
evidence of malignancy in the persistent lymphocele.
Discussion
Lymphoceles are one of the commonest complication after
pelvic surgeries for gynecological malignancies, ranging from
16.4-49 %.2 The incidence of lymphocele depends on various
factors like extent of lymph nodal dissection, use of pe-
ri-operative prophylaxis with low molecular weight heparin,
approach used for lymphadenectomy, etc.8 Tam et al. studied
the incidence and natural course of lymphoceles after gy-
naecological oncological surgeries with serial pelvic ultra-
sound studies at 2 weeks, 6 weeks, 3, 6, 9 and 12 months
post-operatively.4 He reported that around 80% lymphoceles
were detected as early as 2 weeks and 96% by 6 weeks
post-surgery. Most of the early detected lymphoceles also
resolved spontaneously within 6 months of surgery. When-
ever indicated, management includes needle aspiration, per-
cutaneous drainage with or without sclerosis, external
drainage or internal drainage with peritoneal marsupializa-
tion.9
It has been hypothesized that receiving post-operative radi-
otherapy may interfere with regenerative process of lym-
phatic endothelium and thus enhance its incidence. But a
direct relationship between radiation therapy and incidence
of lymphoceles has not been proven.10 We did not observe
any new lymphoceles in follow up imaging of the entire
cohort (93 patients) included in this study. Volume of lym-
phocele at the time of simulation and course of radiation is
important as it forms a part of target volume for adjuvant
radiotherapy.6 It may increase the target volume, thus af-
fecting the dose received by normal pelvic organs, especially
while treating with conformal techniques. Also, it is im-
portant to know the change in volume of lymphocele over a
period of time, as changes in volume may necessitate change
in target volume, while treating patients using conformal
radiotherapy techniques like IMRT. Tam et al. has studied
the natural course of pelvic lymhoceles using serial ultraso-
nography scans for patients undergoing pelvic surgery and
reported temporal reduction in the median volume of cysts
from 11.1 ml at 2 weeks post-surgery to 6.4 ml at 6 weeks
post-surgery.4 However limited information is available re-
garding changes in volume between week 6-14 when pa-
tients would be referred for adjuvant radiation. In the pre-
sent study wherein we had daily MVCT at least for half of
the patients we observed minimal change in lymphocele
volume over 5 week course of radiation suggesting that
re-planning may not really be required for a vast majority of
patients.
As far as OAR doses are concerned we observed reduction in
V30 and V40 Gy volumes for bladder and rectum and V15
for bowel bag and large bowel doses, on the inclusion of
lymphocele into the PTV. Furthermore we observed inverse
relationship between lymphocele volume and rectum and
bladder dose. As most of the lymphoceles were located in
internal iliac region the dosimetric advantage as far as OARs
are concerned could be attributed to displacement of OARs
outside the high dose region secondary to pressure effect of
the lymphocele. While we could not evaluate impact of
lymphocele location and OAR doses it is likely that different
lymphocele locations may have a different impact. For ex-
ample a lymphocele at anterolateral external iliac group
could possibly end up increasing bladder and bowel doses
and a lymphocele at common iliac region could possibly
expand target volume increasing bowel doses.
There is lack of strong literature reporting incidence of re-
currence in the lymphoceles. Lymphoceles presenting after 1
year post surgery or persisting for a longer duration should
create a suspicion for recurrence. Cantrell et al. reported two
cases of recurrent squamous cell carcinoma of uterine cervix,
where he has suggested any lymphocele appearing six
months post-operatively has increased likelihood of harbor-
ing recurrent disease and adequate excision of lymphocele
for histo-pathological evaluation is the treatment of choice.11
In our study we did not observe any new lymphoceles on
follow up imaging of 93 patients during the study period.
Only one patient had persistent lymphocele however was
cytologically negative for recurrence.
Conclusion
Post-operative lymphoceles are common in the internal iliac
nodal group. In the present study we did not observe any
appreciable change in lymphocele volume during course of
radiation. Inclusion of lymphocele in the target volume often
led to reduction in bladder and rectum dose. Impact of lym-
phocele location however could not be investigated in the
present study and remains a subject of future research.
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